Hansoh Pharmaceutical Group
$34.14Change from previous close: −3.29%Absolute change: −$1.16
At a glance
- Revenue growth
- +22.57%
- 2025 vs 2024
- Net income growth
- +27.07%
- 2025 vs 2024
- Net margin
- 37.0%
- 2024: 35.7%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 46,605 | 39,900 | 35,071 | 31,658 | 31,672 | 33,039 | 31,942 | 30,002 | 28,845 | 27,160 |
| Current assets | 41,458 | 35,555 | 30,819 | 27,442 | 27,406 | 28,883 | 27,751 | 25,832 | 24,697 | 23,179 |
| Cash and equivalents | 37,383 | 31,549 | 27,104 | 22,622 | 21,745 | 22,435 | 16,917 | 17,615 | 16,978 | 14,702 |
| Short-term investments | — | 8.2 | 17.6 | 780 | 1,431 | 1,937 | 2,089 | 1,471 | 2,086 | 1,882 |
| Receivables | 3,156 | 3,246 | 2,794 | 3,264 | 2,938 | 3,295 | 3,327 | 3,626 | 3,033 | 3,729 |
| Inventory | 686 | 609 | 653 | 651 | 600 | 576 | 600 | 448 | 497 | 410 |
| Net property, plant and equipment | 3,260 | 3,179 | 3,203 | 3,247 | 3,308 | 3,280 | 3,369 | 3,450 | 3,505 | 3,475 |
| Other intangible assets | 482 | 363 | 289 | 245 | 197 | 177 | 132 | 33.4 | 31.8 | 17.0 |
| Long-term investments | 1,327 | 772 | 733 | 702 | 743 | 685 | 677 | 654 | 525 | 395 |
| Current liabilities | 8,490 | 4,395 | 3,601 | 2,695 | 3,433 | 6,863 | 7,416 | 2,620 | 3,208 | 3,024 |
| Accounts payable | 377 | 334 | 269 | 218 | 175 | 164 | 298 | 222 | 240 | 248 |
| Long-term debt | — | — | — | — | — | 39.7 | — | 4,283 | 4,030 | 3,743 |
| Total debt | — | 105 | 117 | — | — | — | — | — | — | — |
| Total liabilities | 8,837 | 4,536 | 3,975 | 2,978 | 3,769 | 7,244 | 7,767 | 7,355 | 7,719 | 7,131 |
| Total equity (incl. minority) | 37,768 | 35,364 | 31,097 | 28,680 | 27,903 | 25,795 | 24,176 | 22,647 | 21,126 | 20,029 |
| Retained earnings | 20,664 | 17,461 | 16,318 | 13,918 | 13,362 | 11,405 | 9,800 | 8,780 | 7,752 | 6,910 |